FDA
-
-
-
-
-
-
-
Quoin Pharmaceuticals submits IND for rare skin disorder treatment
-
-
-
-
-
-
-
Quoin gets FDA feedback that single study may support QRX003 approval
-
-
-
-
-
-
-
Quoin Pharmaceuticals achieves rapamycin loading targets for topical drugs
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update
-
-
-
-
-
-
-
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
-
323,993 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

